NEW YORK, Dec. 20, 2017 /PRNewswire/ -- Cota Inc., a healthcare data and analytics company bridging precision medicine to population health, announced that it supported the research efforts of two novel findings presented by researchers from John Theurer Cancer Center (JTCC) of Hackensack Meridian Health at the American Society of Hematology (ASH) 59th Annual Meeting & Exposition. The Annual Meeting took place last week from December 9-12, 2017 in Atlanta, Georgia. By harnessing its data and analytics tools, Cota enables and accelerates the time-consuming research work needed to complete a new clinical study. Leading up to ASH, Cota provided the analytics and tools that helped hematology researchers from JTCC reach the findings that were presented at the Annual Meeting.
"While the data surge in medicine has helped accelerate new research and innovation, it has also created workflow challenges. Whether it is physically pulling data from patient records or preparing the information for analysis, medical research is labor-intensive. Cota can directly enable and accelerate clinical research efforts by absorbing this burden – extracting and organizing clinical study data – so researchers can focus on the analysis that leads to novel findings like those presented by our colleagues at ASH," said Stuart Goldberg, M.D., chief scientific officer for Cota.
Joshua R. Richter, M.D. led an oral presentation titled, "Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma." Dr. Goldberg and Cota supported the findings presented by Dr. Richter in several ways. This included providing the researchers with Cota's Living with Cancer (LWC) patient reported outcome (PRO) instrument, a statistically validated tool (ASCO Palliative Care Symposium 2016) that evaluates distress from the point of view of the advanced cancer patient. Cota then abstracted detailed clinical information from the patients' electronic health records, collected the survey data on the 239 patients involved in the study and correlated this with survival data. With Cota's analysis, the researchers concluded that, despite major advancements in the treatment of multiple myeloma, additional attention around a patient's quality of life is required.
Lori A. Leslie, M.D. presented a poster titled, "Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL." To support this project, Cota went into the electronic medical records of the 59 patients in the study, abstracted charts and provided researchers with clinical, demographic, genetic, treatment and outcome data. This process, which can take several weeks, is extremely time consuming for researchers and can be done quickly and efficiently with Cota's analytics and data teams.
This work comes on the heels of Cota's recent collaboration with Memorial Sloan Kettering Cancer Center, where Cota is supporting their commitments to improve patient diagnoses and advance cancer treatment and research. To learn more about how academic researchers can work with Cota, please contact firstname.lastname@example.org.
Cota is a healthcare data and analytics company that enables providers, payers and life science companies involved in diagnosing and treating complex diseases to optimize the outcomes of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Address™ (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.
Cota's technology enriches medical records to create research-grade data and joins it with a suite of analysis, visualization and management tools. This enables providers, payers and life science companies to analyze, report on and research outcomes, costs, treatments and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and medicine to improve the lives of patients everywhere. For more information, go to www.cotahealthcare.com
View original content with multimedia:http://www.prnewswire.com/news-releases/cota-supports-research-efforts-behind-novel-findings-presented-at-the-american-society-of-hematology-annual-meeting-300573894.html
SOURCE Cota Inc.